External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home AACR 2021
Roche and Genentech at

AACR 2021

April 10 - April 15
Virtual
aacr.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:30 PM
Duration 15mins Virtual
IMbrave150: efficacy and safety in high-risk patients (pts) receiving atezolizumab▼ (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
RS Finn, S Qin, M Ikeda, P Galle, M Ducreux, TY Kim, HY Lim, M Kudo, V Breder, P Merle, A Kaseb, D Li, Y-H Feng, W Verret, H Shao, A Nicholas, L Li, AX Zhu, AL Cheng
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:30 PM
Duration 10mins Virtual
Atezolizumab▼ (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): updated overall survival (OS) from the randomized Phase III study IMvigor130
Matt Galsky, José Ángel Arranz Arija, Enrique Grande, Maria De Santis, Ian D Davis, Eiji Kikuchi, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente Vazquez, Jian-Ri Li, Peter O'Donnell, Xiaodong Shen, Chooi Lee, Almut Mecke, Sanjeev Mariathasan, Aristotelis Bamias
Oncology | Urogenital Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Virtual
Updated OS analysis of atezolizumab▼ (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130
Ian D Davis, Matthew Galsky, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente Vazquez, Jian-Ri Li, José Ángel Arranz Arija, Aristotelis Bamias, Enrique Grande, Eiji Kikuchi, Almut Mecke, Sanjeev Mariathasan, Xiaodong Shen, Xinhui Huang, Maria De Santis
Oncology | Urogenital Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 10mins Virtual
Efficacy of atezolizumab▼ in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort
Hainsworth J, Friedman C, Kurzrock R, Burris H, Spigel DR, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Shames D, Schulze K, Patel A, Swanton C
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.